AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26328624 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐CA 2 g/d
Number of subjects: 647
Study 26328624 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐CA 4 g/d
Number of subjects: 647
Study 26328624 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil, OO) 4 g/d
Number of subjects: 647
Study 23113989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group balance training three times per week during 12 weeks
Number of subjects: 59
Study 21734600 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (200 mg, twice per day for 5 days)
Number of subjects: 176
Study 21734600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 18815571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic resistance training (8 weeks, 3 days per week, loading between 26 and 48% of 1RM)
Number of subjects: 14
Study 18815571 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 14
Study 16180383 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM method
Number of subjects: 40
Study 16180383 — intervention group
Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 40
Study 15074449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation services received by smokers with COPD (advised to quit, prescribed nicotine patches, referred to a smoking cessation program)
Number of subjects: 1941
Study 15074449 — intervention group
Group type: COMPARATOR
Intervention: Cessation services received by smokers without COPD
Number of subjects: 1941
Study 15074449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation services received by smokers with COPD not interested in quitting
Number of subjects: 1941
Study 10380968 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of fresh blood samples from patients with Alzheimer's disease
Number of subjects: 22
Study 10380968 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of fresh necropsy brain cortical specimens from AD patients
Number of subjects: 22
Study 8874076 — intervention group
Group type: EXPERIMENTAL
Intervention: polyI:polyC12U (400 or 700 mg) with zidovudine
Number of subjects: 36
Study 8874076 — intervention group
Group type: COMPARATOR
Intervention: placebo with zidovudine
Number of subjects: 36
Study 1502478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 6 months
Number of subjects: 298
Study 1502478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 298
Study 1502478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 1502478 — intervention group
Group type: COMPARATOR
Intervention: Prior omeprazole therapy
Number of subjects: 298
Study 1502478 — intervention group
Group type: COMPARATOR
Intervention: Duration of pre‐trial symptomatic period
Number of subjects: 298
Study 1502478 — intervention group
Group type: COMPARATOR
Intervention: Initial endoscopic severity grade
Number of subjects: 298
Study 6711668 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping rope (purposeful activity)
Number of subjects: 26
Study 6711668 — intervention group
Group type: COMPARATOR
Intervention: Jumping in place without a rope (nonpurposeful activity)
Number of subjects: 26
Study 30962264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/(kg · min) for 10 min before surgery
Number of subjects: 134
Study 30962264 — intervention group
Group type: COMPARATOR
Intervention: Equivalent saline
Number of subjects: 134
Study 29437119 — intervention group
Group type: EXPERIMENTAL
Intervention: RVPAS
Number of subjects: 549
Study 29437119 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock-Tausig shunt
Number of subjects: 549
Study 27312678 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 200 mm Hg, followed by 5 min of reperfusion.
Number of subjects: 1500
Study 27312678 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 60 mm Hg, followed by 5 min of reperfusion.
Number of subjects: 1500
Study 27312678 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC)
Number of subjects: 1500
Study 25326750 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 GOLD classification stages A-D
Number of subjects: 1000
Study 25326750 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 GOLD classification stages 2-4
Number of subjects: 1000
Study 22499291 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 22499291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 22499291 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonist
Number of subjects: 0
Study 22499291 — intervention group
Group type: COMPARATOR
Intervention: β-blocker
Number of subjects: 0
Study 22499291 — intervention group
Group type: COMPARATOR
Intervention: 24-h BP
Number of subjects: 0
Study 22499291 — intervention group
Group type: COMPARATOR
Intervention: Clinic BP
Number of subjects: 0
Study 20364590 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (120 mg/d for 8 weeks)
Number of subjects: 50
Study 20364590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 19091199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pio+SU (pioglitazone plus sulfonylurea)
Number of subjects: 2294
Study 19091199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pio+Met (pioglitazone plus metformin)
Number of subjects: 2294
Study 19091199 — intervention group
Group type: COMPARATOR
Intervention: SU+Met (sulfonylurea plus metformin)
Number of subjects: 2294
Study 17325222 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate
Number of subjects: 360
Study 17325222 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 360
Study 17325222 — intervention group
Group type: COMPARATOR
Intervention: amodiaquine
Number of subjects: 360
Study 12946882 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 26
Study 12946882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 26
Study 12946882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10831027 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 2.5 mg three times daily
Number of subjects: 20
Study 10831027 — intervention group
Group type: COMPARATOR
Intervention: placebo three times daily
Number of subjects: 20
Study 9091392 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 5.9 g/d
Number of subjects: 16
Study 9091392 — intervention group
Group type: COMPARATOR
Intervention: Control (stools collected at least 24 h after the last fecal excretion of PEG)
Number of subjects: 16
Study 8469466 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg four times daily for 7 days
Number of subjects: 143
Study 8469466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg three times daily for 7 days
Number of subjects: 143
Study 3921142 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 477
Study 3921142 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 477
Study 3921142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 30849305 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman's Condom (WC)
Number of subjects: 405
Study 29990228 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based adjunct to standard care (three devices: smartphone with app, portable blood pressure monitor, weight scale)
Number of subjects: 66
Study 29990228 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 66
Study 29990228 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based adjunct to standard care
Number of subjects: 66
Study 26636422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 40 mg
Number of subjects: 12
Study 26636422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 80 mg
Number of subjects: 12
Study 26636422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 120 mg
Number of subjects: 12
Study 26636422 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of febuxostat 40 mg
Number of subjects: 12
Study 26636422 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of febuxostat 80 mg
Number of subjects: 12
Study 23979914 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 205
Study 23979914 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) + Methotrexate (MTX) combination therapy
Number of subjects: 205
Study 21997881 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed pillow treatment (two 15-minute treatments per day for the first 5 days of life)
Number of subjects: 48
Study 21997881 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed pillow treatment
Number of subjects: 48
Study 21997881 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 20088009 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transcatheter delivery of dedicated LAA exclusion devices (PLAATO device, Watchman device, Amplatzer cardiac plug)
Number of subjects: 0
Study 20088009 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 0
Study 18397921 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 142
Study 18397921 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based TIVA
Number of subjects: 142
Study 16362849 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPECT-QGS
Number of subjects: 200
Study 14614003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to subcutaneous (s.c.) at 4 weeks.
Number of subjects: 15
Study 14614003 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to intraperitoneal (i.p.) at 4 weeks.
Number of subjects: 15
Study 14614003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both i.p. and s.c. administration of Flt3-L.
Number of subjects: 15
Study 10585173 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 21
Study 10585173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradelia
Number of subjects: 21
Study 10585173 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm MX
Number of subjects: 21
Study 9114872 — intervention group
Group type: EXPERIMENTAL
Intervention: CBE training
Number of subjects: 82
Study 9114872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 1754109 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular catheter
Number of subjects: 100
Study 1754109 — intervention group
Group type: COMPARATOR
Intervention: Subclavian catheter
Number of subjects: 100
Study 6827423 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (albuterol)
Number of subjects: 40
Study 6827423 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epinephrine
Number of subjects: 40
Study 31908395 — intervention group
Group type: EXPERIMENTAL
Intervention: Same admission (SA) cholecystectomy
Number of subjects: 554
Study 31908395 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 554
Study 31908395 — intervention group
Group type: EXPERIMENTAL
Intervention: Same admission (SA) cholecystectomy (Tokyo Grade 2)
Number of subjects: 554
Study 31908395 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy (Tokyo Grade 2)
Number of subjects: 554
Study 30054629 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated approach with speech-generating device (SGD) intervention
Number of subjects: 140
Study 30054629 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual comparison condition with untrained peers
Number of subjects: 140
Study 27276999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Number of subjects: 367
Study 24566440 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC)
Number of subjects: 16
Study 24566440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 22192488 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual azithromycin treatment
Number of subjects: 24
Study 22192488 — intervention group
Group type: COMPARATOR
Intervention: Twice-yearly azithromycin treatment
Number of subjects: 24
Study 22192488 — intervention group
Group type: COMPARATOR
Intervention: Comparison of annual vs twice-yearly treatment
Number of subjects: 24
Study 22192488 — intervention group
Group type: COMPARATOR
Intervention: Twice-yearly treatment
Number of subjects: 24
Study 21067381 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 234
Study 21067381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 234
Study 17928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium
Number of subjects: 32
Study 17928466 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 32
Study 17928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to mycophenolate mofetil
Number of subjects: 32
Study 16551480 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 204
Study 16551480 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy tonsillectomy
Number of subjects: 204
Study 11881868 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar block with 5 ml of 1:1 mixture of 0.5% plain bupivacaine and 2% lignocaine supplemented with hyaluronidase 300 i.u. ml(‐1)
Number of subjects: 100
Study 11881868 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep topical fornix nerve block anaesthesia (DTFNBA) with placement of a sponge soaked in 0.5% bupivacaine deep into the conjunctival fornices for 15 min
Number of subjects: 100
Study 10211536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg
Number of subjects: 93
Study 10211536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 93
Study 10211536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg
Number of subjects: 93
Study 10211536 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg (Control)
Number of subjects: 93
Study 7638815 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/HFA134a inhaler
Number of subjects: 12
Study 7638815 — intervention group
Group type: COMPARATOR
Intervention: Current salmeterol inhaler
Number of subjects: 12
Study 7638815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HFA134a)
Number of subjects: 12
Study 2611069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid preloading with 1 litre of crystalloid fluid given at a rate of 1000 ml in 15 min before spinal anaesthesia
Number of subjects: 40
Study 2611069 — intervention group
Group type: COMPARATOR
Intervention: No preload group (1 ml min‐1 fluid rate)
Number of subjects: 40
Study 328335 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Brom‐alpha‐ergokryptin (Cb 154)
Number of subjects: 10
Study 328335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual steroids (Estrovis 4000)
Number of subjects: 10
Study 328335 — intervention group
Group type: COMPARATOR
Intervention: Lisurid‐hydrogenmaleate (LHM)
Number of subjects: 10
Study 328335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30977980 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of glasdegib 100 mg (tablet)
Number of subjects: 12
Study 30977980 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous (IV) dose of glasdegib 50 mg
Number of subjects: 12
Study 30977980 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib oral administration
Number of subjects: 12
Study 30977980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet administration
Number of subjects: 12
Study 28547942 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a DVD
Number of subjects: 984
Study 28547942 — intervention group
Group type: COMPARATOR
Intervention: Reading printed materials
Number of subjects: 984
Study 26610558 — intervention group
Group type: EXPERIMENTAL
Intervention: TheaTrim (Purus Labs; containing a branded form of theacrine (Teacrine™) and caffeine (150 mg))
Number of subjects: 20
Study 26610558 — intervention group
Group type: COMPARATOR
Intervention: Caffeine only (150 mg)
Number of subjects: 20
Study 26610558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23628190 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 34
Study 23628190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21940220 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mm Hg intraabdominal pressure (n = 100)
Number of subjects: 200
Study 21940220 — intervention group
Group type: COMPARATOR
Intervention: 10 mm Hg intraabdominal pressure (n = 100)
Number of subjects: 200
Study 19673326 — intervention group
Group type: EXPERIMENTAL
Intervention: Aidi Injection combined with radiotherapy
Number of subjects: 60
Study 19673326 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 60
Study 19673326 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 60
Study 16703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection with hepatic pedicle clamping
Number of subjects: 126
Study 16703653 — intervention group
Group type: COMPARATOR
Intervention: Liver resection without hepatic pedicle clamping
Number of subjects: 126
Study 15094532 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiaxial pedicle screws
Number of subjects: 30
Study 16883915 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenxin Granule (WXG) and amiodarone
Number of subjects: 224
Study 16883915 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 224
Study 10586394 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 375 mg
Number of subjects: 0
Study 10586394 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 1000 mg
Number of subjects: 0
Study 10586394 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 375 mg plus Aztreonam 1000 mg
Number of subjects: 0
Study 7537913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard combination regimens: CMF or CAF)
Number of subjects: 0
Study 7537913 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide/Doxorubicin/5-Fluorouracil)
Number of subjects: 0
Study 7537913 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil)
Number of subjects: 0
Study 7537913 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents (Paclitaxel, Docetaxel, Vinorelbine, Amonafide)
Number of subjects: 0
Study 7537913 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin/5-Fluorouracil
Number of subjects: 0
Study 7537913 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel approaches (differentiating agents, anti-angiogenesis factors, antitumor antigen-based therapy, growth factor receptor/ligand therapy, gene therapy)
Number of subjects: 0
Study 2030804 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d. (n = 62)
Number of subjects: 125
Study 2030804 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. (n = 63)
Number of subjects: 125
Study 2030804 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/nifedipine combination
Number of subjects: 125
Study 2030804 — intervention group
Group type: COMPARATOR
Intervention: Captopril/nifedipine combination
Number of subjects: 125
Study 6786635 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble extract of karela (Momordica charantia)
Number of subjects: 15
Study 6786635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried karela fruits consumed as a daily supplement
Number of subjects: 15
Study 30076692 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 µs; 50 Hz TENS program
Number of subjects: 80
Study 30076692 — intervention group
Group type: COMPARATOR
Intervention: 50 µs; 2 Hz TENS program (Control)
Number of subjects: 80
Study 28119114 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel
Number of subjects: 110
Study 28119114 — intervention group
Group type: COMPARATOR
Intervention: Classic wound dressing (control)
Number of subjects: 110
Study 26842665 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 24 g
Number of subjects: 14
Study 26842665 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MD) 24 g
Number of subjects: 14
Study 26842665 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study 24476806 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted group (less restricted hip movement and assistive devices according to individual needs)
Number of subjects: 365
Study 24476806 — intervention group
Group type: COMPARATOR
Intervention: Restricted group (rehabilitation with restrictions in hip movement and a standard package of assistive devices)
Number of subjects: 365
Study 24476806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 365
Study 23155025 — intervention group
Group type: COMPARATOR
Intervention: Control diet based on corn and soybean meal formulated with 22% CP (dig Gly+Ser:Lys ratio of 147)
Number of subjects: 1050
Study 23155025 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with a 3% CP reduction (19% CP) and a Gly+Ser:Lys ratio of 127
Number of subjects: 1050
Study 23155025 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with a 3% CP reduction (19% CP)
Number of subjects: 1050
Study 23155025 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with increased dig Gly+Ser:Lys ratios from 127 to 137 and 147
Number of subjects: 1050
Study 19863455 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 652
Study 19863455 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 652